drugset / Trial / NCT03219008

Summary

Major Depressive Disorder is one of the most common mental diseases,which increases health-care costs and the financial burden to families and societies. Considering its complex clinical symptoms and diversity of comorbidity, depressive disorder's recognition,diagnosis,and antihistone are based on symptomatology,which is lack of multidimensional diagnosis technique based on clinical pathological characteristics,as well as lack of individualized therapy strategy based on quantified evaluation. Besides, other physical diseases,such as nervous system diseases, cardiovascular diseases,endocrine diseases, have the high comorbidity of depressive disorder. However,there is no precise diagnosis technique or standardized therapy strategy. With all those taken into consideration,our study is aimed to adopt E-mental health and m-Health to explore multi-dimensional diagnosis, individualized therapy and management technique based on molecular biology,nerve electrophysiology,and neuroimaging technology etc.

Timeline

Start
2017-08-01
Primary completion
2019-12
Completion
2020-12

Outcome

Missed primary endpoint

paper There were no differences in the 17-HDRS (P=0.099), QIDS-SR (P=0.407), and QOL-6 (P=0.485) scores among the four groups. PMID 35018097 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule — —
Subject Fluoxetine Small molecule — —
Subject Fluvoxamine Unknown — —
Subject Lithium Unknown — —
Subject Mirtazapine Other / unclassified — —